Making It Possible
NDA Filed December 2020
Anticipated Approval 2021
Estimated US Market Size: $250M
Currently in Phase 3 Studies
Planned Phase 3 Completion 2022
Estimated US Market Size $7.7B
*Outlicensed to Asia
Currently in Phase 3 Studies
Planned Phase 3 Completion 2024
Estimated US Market Size $5.0B
*Outlicensed to USA, Canada, Asia
We are creating transformative therapies currently being studied for use in progressive myopia, presbyopia, and mydriasis. We believe that our innovation in ophthalmic delivery will change the way eyecare professionals and patients view eye medications. Eyenovia strives to create drug therapies that are more effective, safer, and smarter than traditional eyedroppers. Our Optejet® dispenser is designed to deliver minimal amounts of medication to the eye, horizontally, while maintaining similar efficacy to traditional eyedropper treatment. The Optejet® also comes equipped with Bluetooth capability, to help track patient compliance and adherence more easily.
We envision the Optejet®’s technology being utilized for additional applications and drug therapies. Reduction in systemic exposure and toxicity with the Optejet®’s microdosing, compared to a traditional eyedropper, could mean the dispenser may have a better tolerability and safety profile than existing topical treatments. For therapies where adherence is vital to treatment success, the Optejet® can assist with patient compliance.
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today provided a corporate update on its pipeline with recent and upcoming milestones. Positive Phase 3 VISION-1 Results Eyenovia previously announced initial topline data from its Phase 3 VISION-1 clinical […]